A Novel Concept of Reversing Neuromuscular Block¶
Bom. (2002). A Novel Concept of Reversing Neuromuscular Block: Chemical Encapsulation of Rocuronium Bromide by a Cyclodextrin-Based Synthetic Host.
Cited by¶
1 citation across 1 artifact.
Each citation links to the sentence it supports in the citing article.
Domain-specific¶
- Pharmacodynamic Antagonism
- Non-competitive antagonism: the antagonist binds an allosteric site or a downstream effector step, reducing the agonist's maximum possible effect and producing a ceiling that higher agonist doses cannot overcome. Functional or physiological antagonism: the two agents act through entirely different receptors or mechanisms whose downstream physiological outputs oppose each other — a beta-agonist bronchodilator partially antagonised by a systemic beta-blocker, or the blood-pressure-raising effect of vasopressors opposing the vasodilatory effect of an antihypertensive — producing opposition without direct receptor competition. Chemical antagonism: one agent inactivates the other in solution before either reaches its effector, as when sugammadex encapsulates and neutralises rocuronium in plasma, an example more common in anaesthesia reversal than in receptor pharmacology.
This sourceThe original report that a cyclodextrin-based synthetic host abolishes rocuronium-induced neuromuscular blockade by forming a tightly bound binary complex with it.
Supported in partVerified against the publisher's abstract
“Die hierdurch hervorgerufene neuromuskuläre Blockade wird durch die Bildung eines fest gebundenen, binären Komplexes (Ka≈ 107 M−1) zwischen dem Gastmolekül Rocuroniumbromid und einer synthetischen Wirtverbindung auf Cyclodextrinbasis (siehe Struktur im Kristall) aufgehoben.”
- Non-competitive antagonism: the antagonist binds an allosteric site or a downstream effector step, reducing the agonist's maximum possible effect and producing a ceiling that higher agonist doses cannot overcome. Functional or physiological antagonism: the two agents act through entirely different receptors or mechanisms whose downstream physiological outputs oppose each other — a beta-agonist bronchodilator partially antagonised by a systemic beta-blocker, or the blood-pressure-raising effect of vasopressors opposing the vasodilatory effect of an antihypertensive — producing opposition without direct receptor competition. Chemical antagonism: one agent inactivates the other in solution before either reaches its effector, as when sugammadex encapsulates and neutralises rocuronium in plasma, an example more common in anaesthesia reversal than in receptor pharmacology.
Verification¶
Does it exist? Not checked yet. This work's DOI is recorded above but has not been resolved against an external catalogue, so nothing here confirms the work exists.
Does it back the claim? Read against the text for 1 of 1 citation: 1 supported in part. Each verdict is shown under its citation below, with what in the work backs the sentence.
Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.
See how references were verified.
Registry ID ref:243602deb661 · see in the full table